阿拉伯半乳聚糖硫酸盐体内抗肿瘤研究

Study on antitumor actions of arabinogalactan sulfate in vivo

对阿拉伯半乳聚糖硫酸盐（AGS）进行小鼠急性毒性试验,得到其LD50.并确定AGS给药量分别为400、200、100 mg/kg.通过对小鼠腋下移植实体肉瘤S180以及移植腹水瘤H22进行体内抑瘤试验并考察了AGS对荷瘤动物免疫器官胸腺和脾脏的影响.结果表明,AGS的LD50为5 382.8 mg/kg,95%可信范围为4 648.4～6 378.0 mg/kg.各剂量组AGS均表现出一定的抑瘤作用,且具有一定的免疫增强作用,与阴性对照组比较有明显差异（P〈0.01）.

The value of LD50 of arabinogalactan salfate （AGS） was determined by acute poisoning experiment on mice and the doses of AGS are 400,200,100 mg/kg , respectively. The influences of AGS on thymus and spleen index were studied in vivo. The results showed that the LD50 of AGS was 5 382.8 mg/kg and the credibility of 95 % was 4 648.4 - 6 378.0 mg/kg. The three dose groups have inhibitive tumor cells growth actions and improving immune functions.